Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Vít K Procházka, Štěpánka Matuštíková, Tomáš Fürst, Dr., David Belada, MD PhD, Andrea Janíková, MD PhD Assoc Prof, Kateřina Benešová, MD PhD, Heidi Mociková, MD, Juraj Ďuraš, MD, Jan Pirnos, MD, Kateřina Kopečková, MD PhD, Vít Campr, MD PhD, Jozef Michalka, MD, Robert Pytlík, MD, Tomáš Papajík, MD prof, Marek Trněný, MD prof

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139830

Published: 2020

Journal Articles

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Vit K Prochazka, MD prof, David Belada, MD PhD, Andrea Janikova, MD PhD Assoc Prof, Katerina Benesova, MD PhD, Heidi Mocikova, MD PhD, Juraj Duras, MD, Robert Pytlik, MD PhD, Jan Pirnos, MD, Alice Sýkorová, MD PhD, Vit Campr, MD PhD, Jozef Michalka, MD, Kateřina Kopečková, MD PhD, Jitka Dlouha, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3983.

https://doi.org/10.1182/blood-2019-129756

Published: 2019

Journal Articles

Population-Based Analysis of Elderly Patients (>70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry

Andrea Janikova, MD PhD, Assoc Prof, Robert Pytlik, MD, Pavel Klener, MD PhD, Zbynek Bortlicek, PhD, Vit Campr, MD PhD, Natasa Kopalova, Mgr, Katerina Benesova, MD PhD, Michaela Hamouzova, David Belada, MDPhD, Vit Prochazka, MD PhD ass. prof., Jan Pirnos, MD, Juraj Duras, MD, Heidi Mocikova, MD, PhD, Jiri Mayer, MD, Marek Trneny

Blood (2016) 128 (22): 3000.

https://doi.org/10.1182/blood.V128.22.3000.3000

Published: 2016

Journal Articles

Targeting C -Myc Promoter: Helquats As Novel G-Quadruplex Stabilizing Ligands

Erika Kuzmova, PhD, Jaroslav Kozak, M.S., Veronika Komarkova, BSc., Robert Pytlik, MD, PhD, Filip Teply, PhD, Hajek Miroslav, PhD

Blood (2014) 124 (21): 2159.

https://doi.org/10.1182/blood.V124.21.2159.2159

Published: 2014

Journal Articles

The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)

Marek Trneny, MD, Pavel Klener, MD, David Belada, MD, Heidi Mocikova, MD, PhD, Vit Prochazka, MD, Samuel Vokurka, MD PhD, Jan Pirnos, MD, Katerina Kubackova, MD, Juraj Duras, MD, Jana Salkova, MD, David Salek, MD, Robert Pytlik, MD, PhD, Lucie Barsova, MD, Petr Kessler, MD, Ludmila Boudova, MD, Vit Campr, MD, PhD, Radek Jaksa, MD, Jitka Dlouha, Katerina Benesova, MD

Blood (2014) 124 (21): 4425.

https://doi.org/10.1182/blood.V124.21.4425.4425

Published: 2014

Journal Articles

Defining Criteria for Diagnosis of Occult Lymphomatous Involvement in Cerebrospinal Fluid

Heidi Mocikova, MD, PhD, Magdalena Klanova, MD, Martin Spacek, MD, PhD, Robert Pytlik, MD, PhD, Tomas Kozak, MD, PhD, Prof., Marek Trneny, MD, PhD, Prof., Vit Pospisil, PhD

Blood (2014) 124 (21): 5412.

https://doi.org/10.1182/blood.V124.21.5412.5412

Published: 2014

Journal Articles

Observational Study Alternating R-CHOP21 and R-Cytarabine (3+3 Cycles) for Patients with Newly Diagnosed Mantle Cell Lymphoma Not Eligible for High-Dose Therapy: A Czech Lymphoma Study Group Trial Preliminary Results

Pavel Klener, MD, PhD, Eva Fronkova, MD, PhD, Robert Pytlik, MD, PhD, Marketa Kalinova, D.Sc., PhD, Kristina Forsterova, D.Sc., PhD, David Belada, MD, Martin Simkovic, MD, David Salek, MD, PhD, Heidi Mocikova, MD, PhD, Vit Prochazka, MD, PhD, Vit Campr, MD, PhD, Radek Jaksa, MD, Jozef Kubinyi, MD, PhD, Jiri Dolezal, MD, PhD, Ass.Prof., Jan Trka, MD, PhD, Prof., Marek Trneny, MD, PhD, Prof.

Blood (2014) 124 (21): 1720.

https://doi.org/10.1182/blood.V124.21.1720.1720

Published: 2014

Journal Articles

Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database

Andrea Janikova, MD, PhD, Zbynek Bortlicek, Vit Campr, MD, Ph.D., Leos Kren, MD, PhD, David Belada, M.D., Ph.D., Vit Prochazka, M.D., Ph.D., Robert Pytlik, MD, Ph.D., Jan Pirnos, MD, Milan Matuska, MD, PhD, Tomas Papajik, MD, PhD, ass. prof., Heidi Mocikova, MD, PhD, Samuel Vokurka, MD, PhD, Jiri Mayer, MD, PhD, Marek Trneny, MD, Ph.D., Prof.

Blood (2013) 122 (21): 4387.

https://doi.org/10.1182/blood.V122.21.4387.4387

Published: 2013

Journal Articles

Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy?

Andrea Janikova, MD, PhD, Katerina Benesova, MD, Zbynek Bortlicek, Vit Campr, MD, Ph.D., Natasa Kopalova, David Belada, M.D., Ph.D., Vit Prochazka, M.D., Ph.D., Robert Pytlik, MD, Ph.D., Samuel Vokurka, MD, PhD, Jan Pirnos, MD, Milan Matuska, MD, PhD, Heidi Mocikova, MD, PhD, Jiri Mayer, MD, PhD, Marek Trneny, MD, Ph.D., Prof.

Blood (2013) 122 (21): 4388.

https://doi.org/10.1182/blood.V122.21.4388.4388

Published: 2013

Journal Articles

Frontline Intensive Chemotherapy Brings Survival Benefit In Young, Risky Patients With Follicular Lymphoma: Pair-Matched Analysis From The Czech Lymphoma Study Group (CLSG) Database

Vit Prochazka, M.D., Ph.D., Marek Trneny, MD, Ph.D., Prof., Andrea Janikova, MD, PhD, David Belada, M.D., Ph.D., Tomas Kozak, M.D., Ph.D., ass. prof., Tomas Papajik, MD, PhD, ass. prof., Vit Campr, MD, Ph.D., David Salek, MD, Ph.D., Robert Pytlik, MD, Ph.D., Alice Sykorova, MD, PhD, Milada Jankovska, MD, Jitka Dlouha

Blood (2013) 122 (21): 4354.

https://doi.org/10.1182/blood.V122.21.4354.4354

Published: 2013

Journal Articles

Randomized Controlled Trial of Two Different Dosing Regimens of Palifermin to Prevent Mucositis In Multiple Myeloma Patients Receiving One-Day Administration of High-Dose Melphalan

Nicole M.A. Blijlevens, MD, PhD, Maarten E de Chateau, MD, PhD, Gergely Krivan, MD, Werner Rabitsch, MD, Arpad Szomor, MD, Robert Pytlik, MD, Agneta Lissmats, PhD, Hans Erik Johnsen, MD, Tapani Ruutu, MD, Hermann Einsele, MD, Dietger W Niederwieser, MD

Blood (2010) 116 (21): 904.

https://doi.org/10.1182/blood.V116.21.904.904

Published: 2010

Journal Articles

The Rituximab Treament for Relapsed Follicular Lymphomas Changes the Duration of Subsequent Responses. the Analysis on Behalf of CLSG

Marek Trneny, MD, PhD, Robert Pytlik, MD, David Belada, MD, PhD., Katerina Kubackova, MD, Milada Jankovska, MD, Tomas Papajik, MD., PhD., Jan Pirnos, MD, Hana Krejcova

Blood (2008) 112 (11): 1014.

https://doi.org/10.1182/blood.V112.11.1014.1014

Published: 2008

Journal Articles

Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era

David Salek, MD, Ingrid Vasova, MD, Robert Pytlik, MD, David Belada, MD, PhD, Tomas Papajik, MD, PhD, Katerina Kubackova, MD, Jan Pirnos, MD, Ludmila Boudova, MD, PhD, Roman Kodet, MD, Petra Obrtlikova, MD, Hana Krejcova, Marek Trneny, MD, PhD

Blood (2008) 112 (11): 3745.

https://doi.org/10.1182/blood.V112.11.3745.3745

Published: 2008

Journal Articles

Rituximab Combination with Anthracyclin Based Chemothrapy Significantly Improved the Outcome of Young Patients with Diffuse Large B-Cell Lymphoma in Low as Well in High Risk Subgroups.

Marek Trneny, MD, David Belada, MD, Ingrid Vasova, MD, Robert Pytlik, MD, Tomas Kozak, MD, Alice Sykorova, MD, Katerina Kubackova, MD, Jan Pirnos, MD, Ingrid Bolomska, MD, Marketa Petrova, Ing

Blood (2005) 106 (11): 2444.

https://doi.org/10.1182/blood.V106.11.2444.2444

Published: 2005

Journal Articles

Rituximab, Fludarabin and Cyclophosphamide Followed by High Dose Therapy with Autologous Stem Cell Rescue Leads to High Molecular Remission Rate in Chronic Lymphocytic Leukemia patients but Relapses Are Observed.

Marek Trneny, MD, PhD, Jana Salkova, MD, Josef Karban, MD, Jan Cerny, MD, Kyra Michalova, MD, Jan Stritesky, MD, Jiri Schwarz, MD, PhD, Robert Pytlik, MD, Alena Slavickova, MD, PhD

Blood (2004) 104 (11): 3480.

https://doi.org/10.1182/blood.V104.11.3480.3480

Published: 2004

NARROW

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Population-Based Analysis of Elderly Patients (>70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry

Targeting C -Myc Promoter: Helquats As Novel G-Quadruplex Stabilizing Ligands

The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)

Defining Criteria for Diagnosis of Occult Lymphomatous Involvement in Cerebrospinal Fluid

Observational Study Alternating R-CHOP21 and R-Cytarabine (3+3 Cycles) for Patients with Newly Diagnosed Mantle Cell Lymphoma Not Eligible for High-Dose Therapy: A Czech Lymphoma Study Group Trial Preliminary Results

Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database

Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy?

Frontline Intensive Chemotherapy Brings Survival Benefit In Young, Risky Patients With Follicular Lymphoma: Pair-Matched Analysis From The Czech Lymphoma Study Group (CLSG) Database

Randomized Controlled Trial of Two Different Dosing Regimens of Palifermin to Prevent Mucositis In Multiple Myeloma Patients Receiving One-Day Administration of High-Dose Melphalan

Management of Relapsed/Refractory Hodgkin Lymphomas After ASCT in Czech Republic.

The Rituximab Treament for Relapsed Follicular Lymphomas Changes the Duration of Subsequent Responses. the Analysis on Behalf of CLSG

Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era

Rituximab Combination with Anthracyclin Based Chemothrapy Significantly Improved the Outcome of Young Patients with Diffuse Large B-Cell Lymphoma in Low as Well in High Risk Subgroups.

Rituximab, Fludarabin and Cyclophosphamide Followed by High Dose Therapy with Autologous Stem Cell Rescue Leads to High Molecular Remission Rate in Chronic Lymphocytic Leukemia patients but Relapses Are Observed.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only